|

OriV508 Injection Clinical Trials

1 actively recruiting trial

Also known as: OriV508

Pipeline

Early 1: 1

Top Sponsors

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1

Indications

  • Non-Hodgkin Lymphoma (NHL)1
  • Multiple Myeloma (MM)1
  • Cancer1

Other1 trial

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.